Article Sidebar

Submitted
12 January 2021
Accepted
12 January 2021
Published
31 December 2020
Download
PDF
Statistic
Read Counter : 575 Download : 490

Main Article Content

Abstract

Nasopharyngeal carcinoma has a high incidence and mortality rate in Southeast Asia and Indonesia. Radioresistance is a major obstacle to successful treatment of nasopharyngeal carcinoma. DNA repair in the cell cycle and angiogenesis factors affects the response of tumor cells to radiotherapy. Cyclin D1 that functions in the cell cycle process and VEGF as an angiogenesis factor are considered to play a role in the occurrence of radioresistance. The objective of this study is to find the association between immunoexpression of Cyclin D1 and VEGF with radiotherapy response in undifferentiated nasopharyngeal carcinoma. This study used a retrospective case control analysis design, secondary data from medical records of patients diagnosed as undifferentiated nasopharyngeal carcinoma who received complete radiotherapy at the Radiation Oncology Department  Dr Hasan Sadikin Bandung were taken. There were 44 samples divided into radiosensitive (22 samples) and radioresistant (22 samples) groups. Immunohistochemical examination of Cyclin D1 and VEGF was performed on paraffin blocks of patients' biopsy. Data analysis using Chi-Square test (p ≤0.05) , OR 95% CI. Cyclin D1 expressed strongly in 86.4% of the radioresistant group and 59.1% in the radiosensitive group (p<0.05) and the OR 4,385 (0.993-19.356), VEGF was strongly expressed in 77.3% of the radioresistant group and 54.5% in the radiosensitive group (p>0.05). As conclusion, there were significant association between Cyclin D1 with radiotherapy respons in undifferentiated nasopharyngeal carcinoma. The stronger immunoexpression of Cyclin D1, the higher likelihood of radioresistancy. VEGF immunoexpression showed no significant association with radiotherapy response.

Keywords

Cyclin D1 Nasopharyngeal Carcinoma Radiotherapy VEGF

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

How to Cite
Nurhidayat, A. A., Afiati, A., Usman, H. A., & Hernowo, B. S. (2020). The Role of Cyclin D1 and VEGF in Radiotherapy Response of Advance Stage Undifferentiated Nasopharyngeal Carcinoma. Folia Medica Indonesiana, 56(4), 248–253. https://doi.org/10.20473/fmi.v56i4.24554
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Adham M, Kurniawan A & Muhtadi A (2012). Nasopharyngeal Carcinoma in Indonesia: epidemiology, incidence, signs, and symptoms at presentation. Chin J Cancer, 31, 185-196.
  2. Barker HE, Paget JTE, Khan A, Harrington KJ (2015). The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nature, 15, 409-425.
  3. Feng XP, Yi H, Li MY et al (2010). Identification of Biomarkers for Predicting Nasopharyngeal Carcinoma Response to Radiotherapy by Proteomics. Cancer Res, 3450-3462.
  4. Fu SM, Xu FM, Lin SM, Liang Z, Cai JH (2014). Association of cyclin D1 and survivin expression with sensitivity to radiotherapy in patients with nasopharyngeal carcinoma. Genet. Mol. Res., 13, 3502-3509.
  5. Hendarsih E, Oehadian A, Sumantri R, Supandiman I, Hernowo BS (2015). Ekspresi Vascular Endothelial Growth Factor dan Ekspresi Tissue Factor berdasarkan Respons Terapi Kemoradiasi Cisplatin pada Penderita Karsinoma Nasofaring Stadium Lanjut. MKB, 49-54.
  6. Homer JJ, Greenman J, Stafford ND (2001). The expression of vascular endothelial growth factor (VEGF) and VEGF-C in early laryngeal cancer: relationship with radioresistance. Clin. Otolaryngol., 26, 498-504.
  7. Jirawatnotai S, Hu Y, Michowski W et al (2011). A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature, 474, 230-233.
  8. Lin H, Chen ZT, Zhu XD et al (2017). Serum CD166: A novel biomarker for predicting nasopharyngeal carcinoma response to radiotherapy. Oncotarget, 1-10.
  9. Padhani AR, Ollivier L (2001). The RECIST criteria: implications for diagnostic radiologists. The British Journal of Radiology, 74, 983-986.
  10. Petersson, F (2015). Nasopharyngealcarcinoma:Areview. Seminars in Diagnostic Pathology, 1-20.
  11. Qiao N, Wang L, Wang T, Li H (2016). Inflammatory CXCL12-CXCR4/CXCR7 axis mediates G-protein signaling pathway to influence the invasion and migration of nasopharyngeal carcinoma cells. Tumor Biol., 37, 8169-8179.
  12. Rizzardi A, Johnson A, Vogel R et al (2012). Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring. Diagnostic Pathology, 7, 42.
  13. Shimura T (2011). Acquired Radioresistance of Cancer and the AKT/GSK3β/cyclinD1 Overexpression Cycle. J. Radiat. Res, 52, 539-544.
  14. Shimura T (2012). Activation of the AKT/cyclin D1/Cdk4 survival signaling pathway in radioresistant cancer stem cells. Oncogenesis, 1-9.
  15. Su H, Jin X, Shen L et al (2015). Inhibition of cyclin D1 enhances sensitivity to radiotherapy and reverses epithelial to mesenchymal transition for esophageal cancer cells. Tumor Biol., 1-9.
  16. Torre L, Bray F, Siegel R et al (2015). Global Cancer Statistics, 2012. CA CANCER J CLIN, 65, 87-108.
  17. White L (2016). Predictive Biomarkers of Cellular Radiosensitivity for Clinical Radiotherapy Treatment (Doctoral Thesis). Dublin Institute of Technology.
  18. Wu Y, Shen Z, Wang K et al (2017). High FMNL3 expression promotes nasopharyngeal carcinoma cell metastasis: role in TGF-β1- induced epithelia-to-mesenchymal transition. Scientific Report, 7, 1-14.
  19. Xuan SH, Zhou YG, Pan JQ, Zhu W, Xu P (2013). Overexpression of integrin αv in the human nasopharyngeal carcinoma associated with metastasis and progression. Cancer Biomarkers, 13, 323-328.
  20. Yang S, Chen J, Guo Y et al (2012). Identification of prognostic biomarkers for response to radiotherapy by DNA microarray in nasopharyngeal carcinoma patients. Inter. Jour. Oncol, 40, 1590-100.
  21. Zhang L, Chen QY, Liu H, Tang LQ, Mai HQ (2013). Emerging treatment options for nasopharyngeal carcinoma. Drug Design, Development and Therapy, 7, 37-52.